(Company name to be changed upon FINRA approval)
MIAMI, FL – December 12, 2025 – 4Cable TV International, Inc. (OTC: CATV), (the “Company”) which is executing a strategic transformation into the biotech and wellness sector, today issues a statement in response to the expected executive action directing the reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA).
The Company believes this impending regulatory shift represents a watershed moment that will drastically lower research barriers and provide institutional legitimacy, significantly accelerating the drug discovery and development objectives of CATV’s proprietary platforms, including its Atlas division.
“The move to Schedule III is the single most important regulatory step to legitimize cannabis research in a generation,” said Michael Feldenkrais, for 4Cable TV International, Inc. “For our Atlas division, this change immediately unlocks doors to institutional partnerships, federal grants, and clinical trials that were previously closed. This is not about past income; it is about future innovation, positioning us to accelerate our genetic research and cement our role as a trusted, federally-aligned leader in cannabis biotech.”
The Strategic Advantage for the Atlas Division
As a company focused on non-plant-touching research and the development of Intellectual Property (IP), the competitive advantage of CATV’s Atlas division will be drastically enhanced by the Schedule III classification in three primary areas:
1. Accelerated Research & Institutional Legitimacy
- Simplified DEA Oversight: Moving to Schedule III, which acknowledges an accepted medical use, will streamline the bureaucratic and stringent DEA registration requirements currently needed for research. This reduction in regulatory friction allows Atlas’s scientists to dedicate more time and resources to the core task of discovery.
- Access to Major Partnerships: Schedule I status created institutional liability barriers, preventing major academic research centers, hospitals, and pharmaceutical firms from collaborating with cannabis-focused entities. Schedule III removes this stigma, opening a massive new landscape of potential partners for CATV’s genetic platforms, accelerating the path to clinical development.
2. Clearer Path to FDA Approval and IP Valuation
- Regulatory Framework: Schedule III substances are subject to FDA oversight, providing a clearer, though still rigorous, regulatory pathway for future cannabis-derived drug candidates to move toward formal approval. This defined framework reduces risk and increases the certainty of market entry for the IP developed by the Atlas division.
- Increased IP Value: The removal of Schedule I status dramatically increases the commercial viability and valuation of the genetic discoveries and compounds developed by the Atlas division. When a path to an FDA-approved, prescription-based medical product becomes feasible, the resulting intellectual property holds significantly higher value for licensing and sale to the broader pharmaceutical market.
3. Financial Catalyst via Reduced Risk and Increased Investment
- Capital Access: The recognition of medical use reduces the overall legal and financial risk associated with cannabis commerce. This change is expected to improve access to standard banking, credit, and insurance services for the entire industry, potentially easing the path for CATV to secure development funding from major institutional investors previously hesitant to engage with a Schedule I industry.
- Targeted Investment: The market-wide liquidity created by 280E relief across the industry is expected to funnel capital into R&D and quality assurance, creating a greater demand for the kind of federally-aligned, high-quality biotech and testing services offered by the Atlas platform.
About 4Cable TV International, Inc. (CATV) / Category V Biotech, Inc.
4Cable TV International, Inc. (OTC: CATV), is a forward-thinking biotechnology company dedicated to the research, development, and commercialization of innovative products in the cannabis and wellness sectors. Through strategic acquisitions and internal development—including its cutting-edge Atlas division—CATV is committed to driving scientific advancement, ensuring product quality, and creating shareholder value in the rapidly evolving global market.
Contact:
Michael Feldenkrais
info@catvbt.com
